Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation –Positive Malignancies

This study confirmed vemurafenib as a moderate inhibitor of CYP1A2 in vivo, with a statistically significant drug‐drug inte raction with tizanidine. Caution should be exercised when dosing vemurafenib concurrently with CYP1A2 substrates.
Source: Clinical Pharmacology in Drug Development - Category: Drugs & Pharmacology Authors: Tags: Original Manuscript Source Type: research